Patients with Melanoma needed for a trial to evaluate outcomes of DecisionDx® test results when managed by observation or treated with adjuvant therapy

UVA Tracking #
Principal Investigator
Craig L Slingluff
Adela Mahmutovic
Contact Phone
Official Trial Title
Prognostic Gene Expression Profiling and Adjuvant Therapy in Stage IIIA-B Cutaneous Melanoma (PERSONALize)
Study Description

The UVA Cancer Center seeks adults ages 18 and over with Stage IIIA and B cutaneous melanoma for a clinical trial. The DecisionDx®-Melanoma gene expression assay (test) was developed to determine the risk of metastasis (spread of disease) in early stage melanoma patients. As the DecisionDx®-Melanoma test has been shown to be able to identify Stage III patients with low and high risks of their cancer spreading, it could also help predict which patients are less likely to benefit from therapy after surgery and may only need to be watched more closely with visits to your doctors’ office and imaging scans like CTs or PET scans. It may also help find high-risk patients who may benefit more from additional therapy. This study is being done to learn the outcomes of Stage IIIA-B patients and how it relates to DecisionDx®-Melanoma test results.

Participation may last up to 3 years. There is no change to your regular medical care if you take part. This study will only collect information about you and a sample from your tumor that has already been removed.

Study specific tests will be provided at no cost to you. There is no direct benefit for taking part in this study. Information learned from taking part in this study may help other patients in the future.


$35 per visit.